Tropoxin – Drug for the Treatment of Migraine

Anew antimigraine drug – Tropoxin (3-(3,4,5-trimethoxybenzoyloxyimino)-8-methyl-8-azabicyclo[ 1 – 3 ]octane hydrochloride) – was developed and was found to prevent or significantly weaken the constrictor reactions of cerebral arteries evoked by serotonin (5-HT) or the 5-HT 2B/2C receptor agonist met...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal 2016-04, Vol.50 (1), p.19-23
Main Authors: Gan’shina, T. S., Gorbunov, A. A., Gnezdilova, A. V., Turilova, A. I., Kostochka, L. M., Pyatin, B. M., Avdyunina, N. I., Grushevskaya, L. N., Mirzoyan, R. S.
Format: Article
Language:English
Subjects:
Drug therapy
Histamine
Medicine
Migraine
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anew antimigraine drug – Tropoxin (3-(3,4,5-trimethoxybenzoyloxyimino)-8-methyl-8-azabicyclo[ 1 – 3 ]octane hydrochloride) – was developed and was found to prevent or significantly weaken the constrictor reactions of cerebral arteries evoked by serotonin (5-HT) or the 5-HT 2B/2C receptor agonist meta -chlorophenylpiperazine (m-CPP) in intact animals and in animals with ischemic brain damage. Tropoxin showed affinity for5-HT 2 receptors in the brain and had antiaggregatory actions. It had no marked neurotropic properties and did not alter blood pressure responses to noradrenaline, acetylcholine, or histamine. Pilot clinical trials of Tropoxin provided evidence that it has high efficacy in the interictal treatment of frequent and severe migraine attacks.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-016-1391-4